Could a common diabetes pill protect new Moms' hearts?

NCT ID NCT06785116

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if dapagliflozin, a diabetes drug, can reduce heart and blood vessel risks in women who had high blood pressure during pregnancy. About 200 participants will take either the drug or a placebo daily for six months after delivery. The goal is to see if the drug improves blood pressure, weight, and heart function, potentially preventing future heart problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-ECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder eclampsia essential hypertension hypertension, pregnancy-induced hypertensive disorder preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••